Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
Congrès National Annuel du GTE 2021
ESMO (European Society for Medical Oncology) Congress
NANETS (North American Neuroendocrine Tumor Society) Symposium
34th Annual Congress of the European Association of Nuclear Medicine (EANM)
7èmes Journées Françaises de Médecine Nucléaire (JFMN)
American Society of Clinical Oncology (ASCO) Annual Meeting
Journées d’Onco-Urologie Médicale (JOUM)
Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)